Covid-19 Research

Mini Review

Imatinib-Dependent Ascites as a Side Effect of Abdominal Surgery

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Mini Review
Subject Medicine Group
OCLC JBRES Record
Jeffrey H Lipton*
Issue: Volume5-Issue8
Pages: 1060-1062
Received: 2024-07-09
Accepted: 2024-08-28
Published: 2024-08-31

Abstract

Atypical fluid retention is an uncommon side effect of imatinib therapy. This case report describes ascites that developed post-Abdominal Aortic Aneurysm (AAA) repair in a man on imatinib for Chronic Myeloid Leukemia (CML), and only resolved on cessation of imatinib therapy.

FullText HTML FullText PDF DOI: 10.37871/jbres1988 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2024 Lipton JH. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Lipton JH. Imatinib-Dependent Ascites as a Side Effect of Abdominal Surgery. J Biomed Res Environ Sci. 2024 Aug 31; 5(8): 1060-1062. doi: 10.37871/jbres1988, Article ID: JBRES1988, Available at: https://www.jelsciences.com/articles/jbres1988.pdf

Subject area(s)

OncologySurgery

References

  1. Marin D, Marktel S, Bua M, Armstrong L, Goldman JM, Apperley JF, Olavarria E (2002) The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica.Sep;87(9):979-88.PMID: 12217811
  2. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 3:S105-12. doi: 10.3816/clm.2007.s.010. PMID: 17382019.
  3. Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, Garcia-Gutiérrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022 Nov;56:100968. doi: 10.1016/j.blre.2022.100968. Epub 2022 May 6. PMID: 35570071.
  4. Huang J, Cai J, Ye Q, Jiang Q, Lin H, Wu L. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study. BMJ Open. 2023 Aug 3;13(8):e071456. doi: 10.1136/bmjopen-2022-071456. PMID: 37536976; PMCID: PMC10401248.
  5. Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. Am J Hematol. 2015 Apr;90(4):E66-72. doi: 10.1002/ajh.23938. Epub 2015 Jan 30. PMID: 25580915.
  6. Ebnöether M, Stentoft J, Ford J, Buhl L, Gratwohl A. Cerebral oedema as a possible complication of treatment with imatinib. Lancet. 2002 May 18;359(9319):1751-2. doi: 10.1016/S0140-6736(02)08616-6. PMID: 12049868.
  7. Moore JC, Dennehey CF, Anavim A, Kong KM, Tiong Ong S. Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2006 May;76(5):444-6. doi: 10.1111/j.1600-0609.2006.00649.x. Epub 2006 Mar 17. PMID: 16548915.
  8. Ostro D, Lipton J. Unusual fluid retention with imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma. 2007 Jan;48(1):195-6. doi: 10.1080/10428190600923157. PMID: 17325868.
  9. Salie R, Silver RT. Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):331-5. doi: 10.3816/CLML.2010.n.065. PMID: 21030345.
  10. Aleem A, Siddiqui N. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate. Leuk Lymphoma. 2005 Jul;46(7):1097-9. doi: 10.1080/10428190500096781. PMID: 16019565.
  11. Kim KW, Shinagare AB, Krajewski KM, Pyo J, Tirumani SH, Jagannathan JP, Ramaiya NH. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol. 2015 Mar-Apr;16(2):304-13. doi: 10.3348/kjr.2015.16.2.304. Epub 2015 Feb 27. PMID: 25741192; PMCID: PMC4347266.
  12. Pappa E, Gkeka M, Kiki I 2nd, Gourna P, Christopoulos C. Diuretic-Resistant Ascites Following Laparoscopic Surgery in a Patient With Chronic Myeloid Leukemia on Imatinib Therapy. Cureus. 2021 Feb 4;13(2):e13127. doi: 10.7759/cureus.13127. PMID: 33728144; PMCID: PMC7935277.
  13. Samanci NS, Guliyev M, Degerli E, Celik E, Turna ZH. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report. J Cancer Res Ther. 2022 Apr-Jun;18(3):792-794. doi: 10.4103/jcrt.JCRT_188_19. PMID: 35900559.
  14. Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, Yim SV, Chung JH. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006 Nov 8;243(1):16-22. doi: 10.1016/j.canlet.2005.11.014. Epub 2006 Jan 4. PMID: 16388897.
  15. Aoyama R, Ishikawa J, Harada K. The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia. J Cardiol. 2020 Feb;75(2):203-207. doi: 10.1016/j.jjcc.2019.07.008. Epub 2019 Aug 12. PMID: 31416783.
  16. Du L, Wei N, Maiwall R, Song Y. Differential diagnosis of ascites: etiologies, ascitic fluid analysis, diagnostic algorithm. Clin Chem Lab Med. 2023 Dec 20;62(7):1266-1276. doi: 10.1515/cclm-2023-1112. PMID: 38112289.
  17. Hsu CC, Hsu JF, Wu KL. Dasatinib-induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review. Respirol Case Rep. 2021 May 7;9(6):e00753. doi: 10.1002/rcr2.753. PMID: 33976882; PMCID: PMC8103079.
  18. Garcia-Horton A, Lipton JH. Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? J Natl Compr Canc Netw. 2020 Oct 1;18(10):1421-1428. doi: 10.6004/jnccn.2020.7627. PMID: 33022650.
  19. Lucero JA, Lipton JH. A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment. Curr Hematol Malig Rep. 2023 Aug;18(4):98-104. doi: 10.1007/s11899-023-00698-4. Epub 2023 May 16. PMID: 37191911.
  20. Huang J, Cai J, Ye Q, Jiang Q, Lin H, Wu L. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study. BMJ Open. 2023 Aug 3;13(8):e071456. doi: 10.1136/bmjopen-2022-071456. PMID: 37536976; PMCID: PMC10401248.
  21. Zhuang W, Xie JD, Zhou S, Zhou ZW, Zhou Y, Sun XW, Yuan XH, Huang M, Liu S, Xin S, Su QB, Qiu HB, Wang XD. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med. 2018 Feb;7(2):317-324. doi: 10.1002/cam4.1286. Epub 2018 Jan 7. PMID: 29316372; PMCID: PMC5806097.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership